Quinazoline derivatives as anticancer drugs: a patent review (2011-present)

Ravez, Severine; Castillo-Aguilera, Omar; Depreux, Patrick; Goossens, Laurence

Document type :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.1517/13543776.2015.1039512

PMID :

25910402

Permalink :

http://hdl.handle.net/20.500.12210/4414

Title :

Quinazoline derivatives as anticancer drugs: a patent review (2011-present)

Author(s) :

Ravez, Severine [Auteur]

Lille Neurosciences & Cognition (LilNCog) - U 1172
Castillo-Aguilera, Omar [Auteur]
Institut de Chimie Pharmaceutique Albert Lespagnol [ICPAL]
Depreux, Patrick [Auteur]

Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - EA 7365
Goossens, Laurence [Auteur]

495476|||Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]

Journal title :

Expert Opinion on Therapeutic Patents

Abbreviated title :

Expert Opin. Ther. Patents

Volume number :

Pages :

789-804

Publication date :

2015

ISSN :

1354-3776

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Introduction: Quinazoline is one of the most studied moieties in medicinal chemistry due to the wide range of biological properties such as the anticancer, antibacterial, anti-inflammatory, antimalarial and antihypertensive ...
Show more >Introduction: Quinazoline is one of the most studied moieties in medicinal chemistry due to the wide range of biological properties such as the anticancer, antibacterial, anti-inflammatory, antimalarial and antihypertensive activities. During the past decades, several patents and articles have been published in international peer-reviewed literature regarding the discovery and development of original and promising quinazoline derivatives for cancer treatment. Although quinazolines are well known to inhibit EGFR, there is also a large panel of other therapeutic protein targets. Areas covered: This review summarized the new patents and articles published about quinazoline derivatives as anticancer drugs since 2011. Expert opinion: Since 2011, a lot of quinazoline compounds have shown EGFR inhibition. Unlike the first-generation EGFR inhibitors, they inhibit both wild-type and mutated EGFR. In recent years, a number of studies on quinazoline synthesis have been reported and used by several medicinal chemistry groups for better and easier development of new derivatives. Therefore, several patents have been approved for the use of quinazoline compounds as inhibitors of other kinases, histone deacetylase, Nox and some metabolic pathways. Because of the large number of proteins targeted, some high structural diversity is observed in patented quinazoline compounds. Due to the vast applications of quinazoline derivatives, development of novel quinazoline compounds as anticancer drugs remains a promising field.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille
Inserm

Collections :

Research team(s) :

Modélisation biopharmaceutique et pharmacocinétique

Submission date :

2019-02-26T17:09:48Z
2022-01-19T08:58:51Z

Version	Link	Modification date
2	20.500.12210/4414*	2022-01-19T08:24:20Z
1	20.500.12210/4414.1	2019-02-26T17:09:48Z

Quinazoline derivatives as anticancer ...

BibTeX

CSV

Excel

RIS

Version history

Quinazoline derivatives as anticancer ... BibTeX CSV Excel RIS

Version history

Quinazoline derivatives as anticancer ...

BibTeX

CSV

Excel

RIS